Nisa Investment Advisors LLC Sells 1,192 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

Nisa Investment Advisors LLC trimmed its holdings in Vaxcyte, Inc. (NASDAQ:PCVX) by 50.1% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 1,189 shares of the company’s stock after selling 1,192 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Vaxcyte were worth $75,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Russell Investments Group Ltd. bought a new stake in shares of Vaxcyte in the 1st quarter worth approximately $30,000. Avior Wealth Management LLC purchased a new position in shares of Vaxcyte in the third quarter worth $178,000. Wells Fargo & Company MN increased its stake in shares of Vaxcyte by 162.5% in the fourth quarter. Wells Fargo & Company MN now owns 3,961 shares of the company’s stock worth $190,000 after buying an additional 2,452 shares during the period. Osaic Holdings Inc. increased its stake in shares of Vaxcyte by 59.9% in the second quarter. Osaic Holdings Inc. now owns 4,073 shares of the company’s stock worth $200,000 after buying an additional 1,526 shares during the period. Finally, Creative Planning purchased a new position in shares of Vaxcyte in the fourth quarter worth $205,000. 96.78% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Vaxcyte

In other Vaxcyte news, CEO Grant Pickering sold 15,000 shares of the business’s stock in a transaction on Tuesday, January 23rd. The shares were sold at an average price of $63.92, for a total transaction of $958,800.00. Following the transaction, the chief executive officer now directly owns 375,814 shares of the company’s stock, valued at approximately $24,022,030.88. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, CEO Grant Pickering sold 15,000 shares of the business’s stock in a transaction on Tuesday, January 23rd. The shares were sold at an average price of $63.92, for a total transaction of $958,800.00. Following the sale, the chief executive officer now owns 375,814 shares in the company, valued at approximately $24,022,030.88. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Andrew Guggenhime sold 8,000 shares of the business’s stock in a transaction on Monday, March 18th. The shares were sold at an average price of $69.02, for a total transaction of $552,160.00. Following the sale, the chief financial officer now owns 95,679 shares in the company, valued at approximately $6,603,764.58. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 101,577 shares of company stock valued at $6,940,475. 3.60% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. Bank of America lifted their target price on shares of Vaxcyte from $67.00 to $80.00 and gave the stock a “buy” rating in a research note on Tuesday, January 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vaxcyte in a research note on Friday, January 12th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $95.00 target price on shares of Vaxcyte in a research note on Wednesday, April 10th. Four analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $78.50.

Vaxcyte Trading Up 0.3 %

Shares of Vaxcyte stock opened at $60.83 on Friday. The company’s fifty day simple moving average is $69.39 and its two-hundred day simple moving average is $61.02. The company has a market cap of $6.62 billion, a P/E ratio of -14.73 and a beta of 0.89. Vaxcyte, Inc. has a 12-month low of $41.57 and a 12-month high of $82.04.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings data on Tuesday, February 27th. The company reported ($1.82) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.93). During the same quarter last year, the firm earned ($0.73) EPS. Analysts predict that Vaxcyte, Inc. will post -4.18 EPS for the current fiscal year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.